AINOS INC (AIMD)
US00902F3038 - Common Stock
We assign a fundamental rating of 1 out of 10 to AIMD. AIMD was compared to 561 industry peers in the Biotechnology industry. Both the profitability and financial health of AIMD have multiple concerns. AIMD has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
AIMD had negative earnings in the past year.
In the past year AIMD has reported a negative cash flow from operations.
AIMD had negative earnings in each of the past 5 years.
In the past 5 years AIMD always reported negative operating cash flow.
1.2 Ratios
AIMD's Return On Assets of -51.43% is in line compared to the rest of the industry. AIMD outperforms 46.49% of its industry peers.
AIMD's Return On Equity of -89.52% is in line compared to the rest of the industry. AIMD outperforms 48.83% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -51.43% | ||
| ROE | -89.52% | ||
| ROIC | N/A |
ROA(3y)-30.18%
ROA(5y)-182.31%
ROE(3y)-44.97%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
AIMD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
AIMD does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AIMD has been reduced compared to 1 year ago.
AIMD has more shares outstanding than it did 5 years ago.
AIMD has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -3.30, we must say that AIMD is in the distress zone and has some risk of bankruptcy.
AIMD has a Altman-Z score of -3.30. This is comparable to the rest of the industry: AIMD outperforms 45.05% of its industry peers.
A Debt/Equity ratio of 0.51 indicates that AIMD is somewhat dependend on debt financing.
The Debt to Equity ratio of AIMD (0.51) is worse than 74.05% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.51 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.3 |
ROIC/WACCN/A
WACC8.97%
2.3 Liquidity
A Current Ratio of 1.37 indicates that AIMD should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.37, AIMD is doing worse than 82.88% of the companies in the same industry.
A Quick Ratio of 1.33 indicates that AIMD should not have too much problems paying its short term obligations.
AIMD has a worse Quick ratio (1.33) than 82.52% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.37 | ||
| Quick Ratio | 1.33 |
3. Growth
3.1 Past
AIMD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -442.44%.
AIMD shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -96.44%.
AIMD shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 8.83% yearly.
EPS 1Y (TTM)-442.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-118.65%
Revenue 1Y (TTM)-96.44%
Revenue growth 3Y82.77%
Revenue growth 5Y8.83%
Sales Q2Q%-100%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
AIMD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
AIMD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AINOS INC
NASDAQ:AIMD (1/8/2025, 8:00:00 PM)
After market: 0.5689 0 (-0.73%)0.5731
-0.08 (-12.64%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners1.11%
Inst Owner Change0%
Ins Owners11.31%
Ins Owner Change3.3%
Market Cap7.93M
AnalystsN/A
Price TargetN/A
Short Float %6.25%
Short Ratio1.49
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 195.22 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.44 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.77
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.46
FCFYN/A
OCF(TTM)-0.46
OCFYN/A
SpS0
BVpS1.3
TBVpS-0.5
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -51.43% | ||
| ROE | -89.52% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-30.18%
ROA(5y)-182.31%
ROE(3y)-44.97%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.51 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 0.07% | ||
| Cap/Sales | 8.37% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.37 | ||
| Quick Ratio | 1.33 | ||
| Altman-Z | -3.3 |
F-Score1
WACC8.97%
ROIC/WACCN/A
Cap/Depr(3y)7.27%
Cap/Depr(5y)34.36%
Cap/Sales(3y)39.26%
Cap/Sales(5y)53.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-442.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-118.65%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-96.44%
Revenue growth 3Y82.77%
Revenue growth 5Y8.83%
Sales Q2Q%-100%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-54.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-61.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-103.83%
OCF growth 3YN/A
OCF growth 5YN/A